Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...
Hosted on MSN5dOpinion
Progressive Snakes Are Shedding Their Skins In Response To Trump And It’s GloriousThe progressive left is going full establishment in service of attacking the new Trump administration. As President Donald ...
Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.
Amgen Inc. (NASDAQ:AMGN – Get Free Report) was the recipient of unusually large options trading on Wednesday.Stock traders bought 21,787 call options on the company. This is an increase of ...
Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.
Amgen is a biotechnology leader with competitive ... Another headwind is the company's large debt load, which has caused interest expenses to increase. It is more than three times greater than ...
Amgen reported strong fourth-quarter earnings ... JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by ...
What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...
We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...
Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...
My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...
RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $320.00. The company’s shares closed yesterday at $289.02.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback